GLP-1 Shortage & Compounding Status in 2026

GLP-1 supply has been a moving target for the past few years, and 2026 is no different. Whether you are trying to fill a prescription for Ozempic, Wegovy, or Zepbound — or weighing a compounded version — understanding the shortage picture helps you make a safer, smarter choice.

Why GLP-1 Shortages Happened

Demand for GLP-1 medications surged faster than manufacturers could scale production. When a drug is in high demand and supply cannot keep up, the FDA can formally list it as being in shortage. That designation matters for more than just availability — it also shapes what compounding pharmacies are legally allowed to do.

Manufacturers have invested heavily in expanding capacity, and supply has improved considerably compared to the peak shortage years. Still, availability can differ by product, by dose, and even by region, so a drug that is easy to find in one pharmacy may be back-ordered at another.

How Shortage Status Affects Compounding

This is the part that trips up a lot of people. The legal room for compounding is tied directly to whether a drug is on the FDA shortage list.

• During an official shortage, compounding pharmacies have broader latitude to prepare copies of a drug that is otherwise commercially made. This is how compounded semaglutide and tirzepatide became widely available.
• Once the FDA declares a drug off the shortage list, that broad latitude narrows. Mass compounding of copies is restricted, and availability shifts to limited, patient-specific situations — for example, a documented clinical need for a formulation the commercial product cannot meet.

In short, when supply catches up, the wide-open era of compounded GLP-1s tends to wind down. That transition does not happen everywhere at once, which is why the status can feel confusing.

For the legal details specific to each drug, see is compounded semaglutide legal and is compounded tirzepatide legal.

What This Means for Compounded GLP-1s

Compounded versions have been popular largely because of price. Cash-pay compounded semaglutide or tirzepatide often runs about $149 to $299 per month, compared with a roughly $1,000 list price for brand-name products.

Before relying on a compounded option, keep a few things in mind:

• They are not FDA-approved. The FDA reviews specific branded products, not compounded formulations, so the same testing and manufacturing oversight does not apply.
• Quality varies by pharmacy. Sourcing, dosing accuracy, and sterility can differ. Favor state-licensed pharmacies and ask how the product is prepared.
• Access can change quickly. If the FDA removes a drug from its shortage list, your source may no longer be able to legally provide it in the same way.

Our Ozempic vs compounded semaglutide comparison walks through the trade-offs side by side.

Verify the Current Status Yourself

Because shortage designations change over time — sometimes month to month — no article can tell you the exact status on the day you read it. Treat the framing here as background, not a live status report.

To check where things stand right now:

1. Look up the FDA drug shortage database for the specific product and dose you need.
2. Ask your pharmacy about current availability, since local stock varies.
3. Talk to your prescriber about alternatives if your usual dose is hard to find.

If Your Medication Is Hard to Find

A supply gap does not have to derail your treatment. A few practical steps can keep you on track:

• Check multiple pharmacies. Availability differs between chains, independents, and mail-order.
• Ask about different doses or pen sizes, which your clinician may be able to adjust safely.
• Explore manufacturer self-pay programs, often around $349 to $499 per month, or telehealth subscriptions in the $199 to $599 range, which can widen your options.
• Consider a different GLP-1 if clinically appropriate. On average, semaglutide (Wegovy) produced about 15% body-weight loss in the STEP 1 trial and tirzepatide (Zepbound) about 21% in SURMOUNT-1, though results vary from person to person.

To compare real-world costs across routes, try our cost calculator, or use find my GLP-1 to match your situation to available options.

The Bottom Line

The GLP-1 shortage story in 2026 is one of gradual improvement rather than a single clean resolution. Supply is better than it was, but it is uneven, and the legal space for broad compounding shrinks as drugs come off the shortage list. If you have relied on a compounded version, plan for the possibility that access could tighten, and keep brand-name and self-pay routes in view as backups.

All figures here are estimates that vary by plan, pharmacy, region, and date, and the FDA shortage status can change at any time — always verify the current status before making a decision.

This is general information, not medical advice — talk to a licensed clinician before starting or changing any medication.